Aytu BioPharma, Inc. reported a net loss of $14.3 million for the fiscal year ending June 30, 2026, compared to a loss of $13.6 million in the previous year. The company's total net revenue decreased by 13.3% to $57.6 million, down from $66.4 million in fiscal 2025. This decline was primarily attributed to a 20.4% drop in revenue from the ADHD Portfolio, which generated $45.8 million, and a 41.4% decrease in the Pediatric Portfolio, which brought in $5.1 million. The company did, however, successfully launch its new product EXXUA, which contributed $6.6 million in revenue during its first year of sales.
In terms of operational changes, Aytu has shifted its focus towards the commercialization of EXXUA, a novel treatment for major depressive disorder (MDD), and has indefinitely suspended its clinical development programs. The company also completed the divestiture of its Consumer Health business in the first quarter of fiscal 2025, allowing it to concentrate on its core prescription pharmaceutical products. Aytu's manufacturing operations for its ADHD medications were transitioned to a U.S.-based third-party manufacturer to enhance efficiency and profitability.
The company’s financial position as of June 30, 2026, showed total assets of $105 million, down from $124.2 million the previous year. Cash and cash equivalents stood at $26.3 million, while accounts receivable decreased to $22.8 million. Aytu's reliance on a limited number of customers is notable, with five significant customers accounting for 83% of gross revenue, raising concerns about customer concentration risk. The company employed 76 individuals, with a focus on enhancing its commercial operations.
Looking ahead, Aytu BioPharma aims to accelerate the adoption of EXXUA and improve its financial performance through operational efficiencies. The company plans to invest in marketing and promotional activities to support the growth of EXXUA, while also managing its existing product portfolios. Despite the challenges posed by inflationary pressures and supply chain disruptions, Aytu remains optimistic about its potential for future profitability, contingent on the successful commercialization of its products and the management of operational costs.
About AYTU BIOPHARMA, INC
Aytu BioPharma, Inc. is a pharmaceutical company specializing in innovative treatments for central nervous system disorders, primarily major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Its core products include EXXUA, a novel selective serotonin 5HT1a receptor agonist for MDD, and extended-release orally disintegrating tablets Adzenys and Cotempla for ADHD. The company also offers pediatric allergy and fluoride supplement products, marketing primarily in the U.S. through third-party wholesalers and an internal sales force.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov